Autosomal dominant polycystic kidney disease: New treatment options and how to test their efficacy

Kidney and Blood Pressure Research

Volumn 32, Issue 5, 2009, Pages 380-387

  Wüthrich, Rudolf P ^a   Serra, Andreas L ^a   Kistler, Andreas D ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Autosomal dominant polycystic kidney disease; Cyst growth; End stage kidney disease

Indexed keywords

ANGIOPEPTIN; EVEROLIMUS; GADOLINIUM; LISINOPRIL; MOZAVAPTAN; OCTREOTIDE; RAPAMYCIN; SOMATOSTATIN; TELMISARTAN; TOLVAPTAN;

AUTOSOMAL DOMINANT DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISEASE COURSE; DRUG EFFICACY; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RECEPTORS, VASOPRESSIN; SOMATOSTATIN;

EID: 70350539427     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000254338     Document Type: Review

References (35)

1. Torres VE, Harris PC, Pirson Y: Autosomal dominant polycystic kidney disease. Lancet 2007; 369: 1287-1301.
2. Grantham JJ: Clinical practice: autosomal dominant polycystic kidney disease. N Engl J Med. 2008; 359: 1477-1485.
3. Cheong B, Muthupillai R, Rubin MF, Flamm SD: Normal values for renal length and volume as measured by magnetic resonance imaging. Clin J Am Soc Nephrol 2007; 2: 38-45.
4. Churchill DN, Bear JC, Morgan J, Payne RH, McManamon PJ, Gault MH: Prognosis of adult onset polycystic kidney disease reevaluated. Kidney Int 1984; 26: 190-193.
5. Hateboer N, V Dijk MA, Bogdanova N, Coto E, Saggar-Malik AK, San Millan JL, Torra R, Breuning M, Ravine D: Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 1999; 353: 103-107.
6. Dalgaard OZ: Bilateral polycystic disease of the kidneys; a follow-up of two hundred and eighty-four patients and their families. Acta Med Scand Suppl 1957; 328: 1-255.
7. Fick-Brosnahan GM, Belz MM, McFann KK, Johnson AM, Schrier RW: Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study. Am J Kidney Dis 2002; 39: 1127-1134.
8. Fick-Brosnahan GM, Tran ZV, Johnson AM, Strain JD, Gabow PA: Progression of autosomal-dominant polycystic kidney disease in children. Kidney Int 2001; 59: 1654-1662.
9. Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr, Wetzel LH, Baumgarten DA, Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman GN, Meyers CM, Zhang X, Zhu F, Miller JP; CRISP Investigators: Volume progression in polycystic kidney disease. N Engl J Med 2006; 354: 2122-2130.
10. Kistler AD, Poster D, Krauer F, Weishaupt D, Raina S, Senn O, Binet I, Spanaus K, Wüthrich RP, Serra AL: Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int 2009; 75: 235-241.
11. Grantham JJ, Chapman AB, Torres VE: Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol 2006; 1: 148-157.
12. King BF, Reed JE, Bergstralh EJ, Sheedy PF 2nd, Torres VE: Quantification and longitudinal trends of kidney, renal cyst, and renal parenchyma volumes in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2000; 11: 1505-1511.
13. Sise C, Kusaka M, Wetzel LH, Winklhofer F, Cowley BD, Cook LT, Gordon M, Grantham JJ: Volumetric determination of progression in autosomal dominant polycystic kidney disease by computed tomography. Kidney Int 2000; 58: 2492-2501.
14. Antiga L, Piccinelli M, Fasolini G, Ene-Iordache B, Ondei P, Bruno S, Remuzzi G, Remuzzi A: Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: a progress report. Clin J Am Soc Nephrol 2006; 1: 754-760.
15. Bae KT, Tao C, Zhu F, Bost JE, Chapman AB, Grantham JJ, Torres VE, Guay-Woodford LM, Meyers CM, Bennett WM; Consortium for Radiologic Imaging Studies Polycystic Kidney Disease: MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement. Clin J Am Soc Nephrol 2009; 4: 719-725.
16. Torres VE, Harris PC: Mechanisms of disease: autosomal dominant and recessive polycystic kidney diseases. Nat Clin Pract Nephrol 2006; 2: 40-55.
17. Torres VE, Harris PC: Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunities. J Intern Med 2007; 261: 17-31.
18. Torres VE, Harris PC: Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 2009; 76: 149-168.
19. Tao Y, Kim J, Schrier RW, Edelstein CL: Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005; 16: 46-51.
20. Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wüthrich RP: Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 2006; 21: 598-604.
21. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, Flask CA, Novick AC, Goldfarb DA, Kramer-Zucker A, Walz G, Piontek KB, Germino GG, Weimbs T: The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 2006; 103: 5466-5471.
22. Wu M, Wahl PR, Le Hir M, Wackerle-Men Y, Wüthrich RP, Serra AL: Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press Res 2007; 30: 253-259.
23. Mostov KE: mTOR is out of control in polycystic kidney disease. Proc Natl Acad Sci USA 2006; 103: 5247-5248.
24. Serra AL, Kistler AD, Poster D, Struker M, Wüthrich RP, Weishaupt D, Tschirch F: Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study. BMC Nephrol 2007; 8: 13.
25. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd: Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 2004; 10: 363-364. (Pubitemid 38508512)
26. Torres VE: Vasopressin antagonists in polycystic kidney disease. Semin Nephrol 2008; 28: 306-317.
27. Reubi JC, Horisberger U, Studer UE, Waser B, Laissue JA: Human kidney as target for somatostatin: high affinity receptors in tubules and vasa recta. J Clin Endocrinol Metab 1993; 77: 1323-1328.
28. Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, Ene-Iordache B, Remuzzi G, Epstein FH: Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 2005; 68: 206-216.
29. Van Keimpema L, Nevens F, Vanslembrouck R, Van Oijen MG, Hoffmann AL, Dekker HM, De Man RA, Drenth JP: Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009 [Epub ahead of print].
30. Schrier RW: Optimal care of autosomal dominant polycystic kidney disease patients. Nephrology (Carlton) 2006; 11: 124-130.
31. Ecder T, Edelstein CL, Fick-Brosnahan GM, Johnson AM, Chapman AB, Gabow PA, Schrier RW: Diuretics versus angiotensinconverting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am J Nephrol 2001; 21: 98-103.
32. Ecder T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW: Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2000; 35: 427-432.
33. Van Dijk MA, Breuning MH, Duiser R, Van Es LA, Westendorp RG: No effect of enalapril on progression in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2003; 18: 2314-2320.
34. Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW: Prospective change in renal volume and function in children with ADPKD. Clin J Am Soc Nephrol 2009; 4: 820-829.
35. Chapman AB: Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies. Clin J Am Soc Nephrol 2008; 3: 1197-1204